文献速递膀胱癌与上尿路尿路上皮癌前列腺增生与排尿功能障碍

非那雄胺使用与多族裔人群膀胱癌风险

Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
PubMed 文献 · J Urol · 2021-02-22

本研究基于纽约布朗克斯学术医疗中心2000至2016年良性前列腺增生患者电子病历数据,纳入42,406例患者,其中27.7%为黑人、14.8%为西班牙裔,13.4%使用非那雄胺。竞争风险分析显示,非那雄胺与整体膀胱癌风险降低36%相关(HR 0.64,95%CI 0.51-0.80,P<0.0001),但分层后仅白人(HR 0.61)和西班牙裔(HR 0.44)风险降低,黑人无关联(HR 1.01)。

要点

  • 非那雄胺与整体膀胱癌风险降低36%相关(HR 0.64,95%CI 0.51-0.80)。
  • 白人(HR 0.61)和西班牙裔(HR 0.44)风险降低,黑人无关联(HR 1.01)。
  • 种族/族裔是未来非那雄胺膀胱癌化学预防研究的重要分层因素。

核心结论

  • 非那雄胺使用与膀胱癌风险降低相关,但该保护作用仅见于白人和西班牙裔男性,黑人男性未见关联。

研究设计与样本

  • 回顾性队列研究,基于纽约布朗克斯学术医疗中心2000至2016年电子病历数据库,纳入42,406例良性前列腺增生患者,平均年龄67±12.9岁。

主要发现

  • 非那雄胺使用者5,698例(13.4%),其中84例(1.5%)诊断膀胱癌;非使用者36,708例,其中762例(2.1%)诊断膀胱癌,log-rank P=0.003。
  • 调整年龄、吸烟和种族/族裔后,非那雄胺与整体膀胱癌风险降低36%相关(HR 0.64,95%CI 0.51-0.80,P<0.0001)。
  • 分层分析显示,白人男性风险降低(HR 0.61,95%CI 0.43-0.86,P=0.005),西班牙裔男性风险降低(HR 0.44,95%CI 0.21-0.90,P=0.026),黑人男性无关联(HR 1.01,95%CI 0.67-1.51,P=0.964)。

临床怎么用

  • 在评估非那雄胺对膀胱癌风险的影响时,应考虑患者的种族/族裔背景,黑人男性可能无法获得相同的化学预防获益。

局限性

  • 本研究为单中心回顾性研究,可能存在处方偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Finasteride use has been associated with a reduced incidence of bladder cancer. However, the majority of studies have been conducted primarily in East Asian or White populations. Given differences in the incidence of bladder cancer among racial/ethnic groups, it is important to determine whether the effect of finasteride use on bladder cancer varies by race/ethnicity. MATERIALS AND METHODS: We identified all patients with a diagnosis of benign prostatic hyperplasia between 2000 and 2016 at our academic health center in Bronx, New York via an electronic medical record database. We then identified patients who were prescribed finasteride, and those who developed bladder cancer during followup. We used competing risk analysis to examine associations of finasteride use with risk of bladder cancer, adjusting for age, smoking and race/ethnicity. RESULTS: We identified 42,406 patients with benign prostatic hyperplasia (average±SD age 67±12.9 years), of whom 27.7% were Black and 14.8% were Hispanic. Finasteride was prescribed in 5,698 patients (13.4%). Bladder cancer was diagnosed in 84 of 5,698 finasteride users (1.5%), compared to 762 of 36,708 nonusers (2.1%, log-rank p=0.003). Finasteride was associated with a 36% reduction in risk of bladder cancer (HR: 0.64, 95% CI: 0.51-0.80; p <0.0001) among all patients. When data were stratified by race/ethnicity, finasteride use was associated with a reduction in risk of bladder cancer in White men (HR: 0.61, 95% CI: 0.43-0.86; p=0.005) and Hispanic men (HR: 0.44, 95% CI: 0.21-0.90; p=0.026), but there was no association among Black men (HR: 1.01, 95% CI: 0.67-1.51; p=0.964). CONCLUSIONS: Our study corroborates previous findings that men who are on finasteride have a lower bladder cancer incidence. However, the reduction in risk was seen only in White and Hispanic men, but not among Black men. Therefore, race/ethnicity represents an important stratification factor for future larger studies on finasteride as chemoprevention for bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Zhu D, Srivastava A, Agalliu I, et al. Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population. J Urol. 2021. PMID: 33617325. doi:10.1097/JU.0000000000001694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。